Systemic zinc-dependent enzymes and zinc-binding proteins

Systemic zinc-dependent enzymes and zinc-binding proteins represent a vast and diverse group of macromolecules that require zinc ions for their structural integrity, catalytic activity, or regulatory functions, encompassing approximately 10% of the human proteome [1.1.4, 1.3.1]. This category includes over 300 distinct enzymes, such as carbonic anhydrases, matrix metalloproteinases (MMPs), and histone deacetylases (HDACs), as well as thousands of structural proteins like zinc-finger transcription factors [1.2.1, 1.2.4]. These proteins are essential for nearly every major biological process, including DNA synthesis, gene expression, cell signaling, and immune function [1.1.1, 1.1.4]. Therapeutically, specific members of this class are highly validated targets; for example, ACE inhibitors are used for hypertension, while HDAC inhibitors are employed in oncology [1.2.1, 1.3.4]. However, because this 'target' is a broad collective, drugs that affect zinc availability or binding non-selectively, such as chelators or broad-spectrum inhibitors, often face significant challenges related to systemic toxicity and off-target effects [1.3.2, 1.3.3].

Other names

Zinc-binding proteomeZinc-dependent metalloenzymesZinc-binding proteinsMetalloenzymesZinc-finger proteins

Drugs interact with this broad class of proteins through several mechanisms: direct inhibition of catalytic activity by binding to the zinc-containing active site, systemic or localized chelation of zinc ions to deplete the available cofactor pool, or supplementation to restore the function of zinc-dependent processes in deficient states [1.2.1, 1.3.2, 1.3.3].